



May 05,2022

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai – 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

**Sub:- Unaudited Financial Results for the quarter ended March 31,2022 and Interim Dividend for the Financial Year 2021-22**

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 6:00 p.m. and ended at 7: 20 p.m.), the Unaudited Financial Results for the quarter ended March 31,2022 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended March 31, 2022;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2022 furnished by Statutory Auditors of the Company

Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended an Interim Dividend for the Financial Year 2021-22 of Rs. 41 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before May 31, 2022.

As informed earlier in our letter dated April 28, 2022, record date for the purpose of eligibility for payment of said Interim Dividend shall be May 13,2022.

Kindly take the same on record and oblige.

Thanking you,  
Yours faithfully,

***For Procter & Gamble Health Limited***

***Zeal Shah***  
***Company Secretary***

**Procter & Gamble Health Limited**

CIN: L99999MH1967PLC013726

Registered Office: Godrej One, 8<sup>th</sup> Floor,

Pirojshanagar, Eastern Express Highway, Vikhroli East,

Mumbai 400 079 | Tel: (91-22) 6866 9000

[www.pghealthindia.com](http://www.pghealthindia.com)



## Procter & Gamble Health Announces Third Quarter Results Showing 14% Growth in Net Profits

Sales of ₹ 262 Crores and PAT of ₹51.2 Crores for quarter ended March 31, 2022

Sales for the quarter up by 23%

**Mumbai, May 5, 2022:** Procter & Gamble Health Limited announced today its financial results for the quarter ended March 31, 2022. The Company has delivered total sales of ₹ 262 crores for the quarter ended March 31, 2022 vs ₹ 214 crores, up by 23% vs year ago. The Profit After Tax (PAT) was ₹ 51.2 crores, up by 224% vs year ago. Increase in PAT is driven by higher sales and lower marketing and depreciation charge vs same period last year. Sales for the nine-month period ending March 31, 2022, were ₹ 803 crores, vs ₹ 710 crores up 13% vs a year ago. PAT for nine-month period is ₹ 151 crore Vs ₹143 crore a year ago, despite high inflationary pressures.

**Mr. Milind Thatte, Managing Director, P&G Health India**, said, *“We have been able to register consistent growth in revenue and earnings in recent quarters. Our strong portfolio of products that address the increasing demand for daily supplementation and a renewed focus on expanded reach and improved productivity continue to form the pillars of our strategy. We will leverage our strengths in medico-marketing, technology and distribution, in order to better serve the consumers and customers who count on us.”*

*“We continue our efforts in promoting consumer education, raising awareness around women’s health and overall health and wellness. This year, we launched ‘Women in Healthcare’ summit as a platform to encourage more women to join the healthcare and pharma sectors. We continue to strengthen and expand our projects under SEHAT, our CSR program that aims at contributing to building a healthier India. Recently, we partnered with Apnalaya, to extend our support to the urban poor and provide care to underprivileged pregnant women, new mothers and newborns,” he added.*

### About Procter & Gamble Health Limited:

Procter & Gamble Health Limited is one of India's largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit [www.pghealthindia.com](http://www.pghealthindia.com) for the latest news and information about Procter & Gamble Health Limited and its brands.

### About Procter & Gamble:

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. The P&G operates in approximately 70 countries worldwide.

### CONTACTS

#### Media Contacts - Procter & Gamble Health Limited:

- Ruchita Mehra | mehra.r@pg.com
- Paromita Kundu | kundu.p.1@pg.com

#### Investor Relations Contact:

- Flavia Machado | [machado.f.1@pg.com](mailto:machado.f.1@pg.com)

#### Registered Office :

**Procter & Gamble Health Limited**  
CIN: L99999MH1967PLC013726  
Godrej One, 8<sup>th</sup> Floor, Pirojshanagar,  
Eastern Express Highway, Vikhroli East,  
Mumbai 400 079 | Tel: (91-22) 6866 9000

#### Site Address:

**Procter & Gamble Health Limited**  
CIN: L99999MH1967PLC013726  
Usgaon, Ponda Taluka,  
Goa 403 407 | Tel: (91-832) 2347105  
[www.pghealthindia.com](http://www.pghealthindia.com)

**PROCTER & GAMBLE HEALTH LIMITED**

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079.  
CIN No. L99999MH1967PLC013726, email: investorgrievance.ln@pg.com

Highly Restrict

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS AND QUARTER ENDED 31 MARCH 2022**

(' in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)	(5)	(6)
		Three months ended 31st March 2022	Preceding Three months ended 31st December 2021	Corresponding Three months ended 31st March 2021	Nine Months ended 31st March 2022	Nine Months ended 31st March 2021	Year ended 30th June 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Revenue from Operations	26,782.0	27,790.0	21,915.0	81,852.0	72,334.0	100,873.0
2.	Other Income	235.0	470.0	324.0	1,009.0	1,568.0	1,810.0
3.	<b>Total Income (1+2)</b>	<b>27,017.0</b>	<b>28,260.0</b>	<b>22,239.0</b>	<b>82,861.0</b>	<b>73,902.0</b>	<b>102,683.0</b>
4.	Expenses						
	a) Cost of materials consumed	7,356.0	9,163.0	7,750.0	25,818.0	21,722.0	28,912.0
	b) Purchases of stock-in-trade	409.0	524.0	360.0	1,584.0	1,302.0	2,116.0
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	317.0	(653.0)	(1,432.0)	(2,033.0)	(492.0)	454.0
	d) Employee benefits expense	4,505.0	4,100.0	3,754.5	12,556.0	10,659.0	15,047.0
	e) Depreciation and amortisation expense	612.0	659.0	767.0	1,961.0	2,288.0	3,004.0
	f) Finance Costs	14.0	12.0	20.0	40.0	63.0	80.0
	g) Other expenses	7,318.0	8,472.0	8,409.5	23,059.0	19,385.0	29,742.0
	<b>Total expenses (4)</b>	<b>20,531.0</b>	<b>22,277.0</b>	<b>19,629.0</b>	<b>62,985.0</b>	<b>54,927.0</b>	<b>79,355.0</b>
5.	Profit before exceptional items and tax (3-4)	6,486.0	5,983.0	2,610.0	19,876.0	18,975.0	23,328.0
6.	Less: Exceptional Items	-	-	-	-	-	-
7.	Profit before tax (5-6)	6,486.0	5,983.0	2,610.0	19,876.0	18,975.0	23,328.0
8.	Tax expenses						
	Current Tax	1,722.0	1,617.0	850.0	5,269.0	5,038.0	6,360.0
	Deferred Tax	(59.0)	10.0	28.0	(109.0)	(113.0)	(490.0)
	Tax for earlier years	(293.0)	(128.0)	155.0	(421.0)	(241.0)	(222.0)
9.	Net Profit for the period/ year (7-8)	5,116.0	4,484.0	1,577.0	15,137.0	14,291.0	17,680.0
10.	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains/(losses) on defined benefit plans	128.0	(336.0)	495.0	(230.0)	(495.0)	56.0
	ii. Income tax effect	(32.0)	84.0	(124.0)	58.0	125.0	(14.0)
	Total Other Comprehensive Income, net of tax	96.0	(252.0)	371.0	(172.0)	(370.0)	42.0
11.	Total Comprehensive Income for the period/year (9+10)	5,212.0	4,232.0	1,948.0	14,965.0	13,921.0	17,722.0
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	-	-	68,711.0
14.	Earnings per equity share (of Rs 10/- each) *(not annualised)						
	(a) Basic and Diluted (In Rs.)	* 30.8	* 27	* 9.5	* 91.7	* 86.1	* 106.5

Notes:

- The above financial results for the quarter and nine months ended March 31, 2022 have been reviewed by the Audit Committee, and approved by the Board of Directors of the Company at their Meeting held on May 5, 2022 and have been subject to a limited review by the Statutory Auditors of the Company.
- Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
- The Company operates under only one segment i.e. Pharmaceuticals. Accordingly, no separate segment information has been provided.
- The Board of Directors at its meeting held on May 5, 2022 has declared for the current year an interim dividend of Rs 41/- per equity share of face value 10 each aggregating to 6,805.75 lakhs.
- Previous period figures have been regrouped/ reclassified wherever necessary.

*Hari Bhatt*  
**HARI BHATT & Co. LLP**

For and on behalf of the Board of Directors of  
Procter & Gamble Health Limited.



*Milind Thattai*  
**Milind Thattai**  
Managing Director

Place : Mumbai  
Date : 5 May 2022  
Please visit us at our website [www.pghealthindia.com](http://www.pghealthindia.com)

# HARIBHAKTI & CO. LLP

Chartered Accountants

**Independent Auditor's Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

To the Board of Directors

Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Procter & Gamble Health Limited ("the Company") for the quarter ended March 31, 2022 and for the period from July 01, 2021 to March 31, 2022 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be



# HARIBHAKTI & CO. LLP

Chartered Accountants

disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048




Hemant J. Bhatt

Partner

Membership No.: 036834

UDIN: 22036834 AILUNC5360



Mumbai

May 5, 2022